Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Search results for

There are 43,001 results that match your search.43,001 results
  • Article 29 of Law 3784/09 revises the provisions of the Unfair Competition Act regarding the limitations period for unfair competition claims.
  • On December 13 2009, the CNNIC, the regulator of the .cn TLD, issued an urgent notice. The gist of the notice was that beginning at 9am on December 14 2009, no individuals are qualified to register a domain name. A domain name applicant is also required to submit a copy of the business licence (or a business bar code certificate) to the domain name registrar.
  • During patent opposition proceedings before the German Patent and Trade Mark Office or an appellate court the opponent may sometimes wish to be substituted. In present legal practice a successful substitution of the opponent requires, inter alia, that the "sphere of interest" be transferred from the former opponent to the new opponent. However, correctly determining the scope of this sphere of interest may result in complex and lengthy legal proceedings.
  • Because pharmaceutical companies perform time-consuming clinical trials before receiving a marketing authorisation (MA) to put a product on the market, the protection offered by pharmaceutical product patents is often reduced by five to 10 years. This reduces the benefits from an IP monopoly.
  • Austrian rules on remuneration for inventions made by employees are in several aspects quite different to those in Germany. Two of them are highlighted here.
  • In our previous columns we have emphasised the importance of exercising duty of candour in the prosecution and preparation of patent applications in Canada. In Ratiopharm Inc v Pfizer Limited, Mister Justice Hughes was very critical of "self-serving" statements in patent applications and found a patent invalid partly on the basis that the invention failed to live up to its claims of being "outstanding" and "markedly better than prior art compounds". In Lundbeck v Ratiopharm (2009), Madam Justice Mactavish revisited the duty of candour during prosecution and held a patent invalid despite the fact that the applicants had expressly drawn a particular piece of prior art to the examiner's attention and despite the fact that she considered the invention was neither anticipated by it nor obvious over it. Her rationale was that the applicants made the general statement that the prior art as a whole taught away from combining two compounds, whereas that was not true of the particular reference in question. This underscores the need to consider the impact of each known reference before making any sweeping generalisations in submissions to the examiner.
  • In 2001, Australia introduced a new form of patent called the innovation patent system. Patents granted under this system have a term of eight years. Significantly, the innovation patent system allows for the grant of patents that would be considered obvious in the US or Europe. Having no obviousness test allows patent holders to exploit what would otherwise be considered a very weak patent.
  • Due to the adoption of TRIPs, several changes were introduced to adapt the Argentine legislation to the Agreement's minimum standards (such as the term of patent protection and the availability of patent rights in all fields of technology, for example).
  • A new trend in US copyright cases could save litigants thousands of dollars in discovery costs. Simon Frankel, Shannon Nestor and John Freed explain how
  • Margaret Shearer at Banki Haddock Fiora explains why efforts to protect packaging and presentation often fail, and lessons from the recent Maltesers case
599
of
4301